Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intra-Cellular Therapies

131.87
+0.0000
Volume:- -
Turnover:- -
Market Cap:14.02B
PE:-182.12
High:131.87
Open:131.87
Low:131.87
Close:131.87
Loading ...

Top Premarket Gainers

MT Newswires Live
·
13 Jan

Pre-Bell|U.S. Futures Slide; Tesla and Nvidia Drop 3%; MicroStrategy Sinks 5%; Moderna Plunges 17%

Tiger Newspress
·
13 Jan

BRIEF-Intra-Cellular Therapies Upon Termination Of Deal, To Pay Johnson & Johnson Termination Fee Of $475.5 Million

Reuters
·
13 Jan

Johnson & Johnson to Acquire Intra-Cellular Therapies for $132 a Share, Confirming Earlier Report

MT Newswires Live
·
13 Jan

S&P 500 Futures Fall In Premarket Trading; Intra-Cellular Therapies, Zurn Elkay Water Solns Lead

Dow Jones
·
13 Jan

Market Chatter: Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6 Billion

MT Newswires Live
·
13 Jan

Johnson & Johnson to Acquire Intra-Cellular in $14.6B Deal

Dow Jones
·
13 Jan

Mizuho Securities Sticks to Their Buy Rating for Intra-Cellular Therapies (ITCI)

TIPRANKS
·
13 Jan

BRIEF-Johnson & Johnson To Acquire Intra-Cellular Therapies for $14.6 billion

Reuters
·
13 Jan

Intra-Cellular Therapies Shares up 35.9% Premarket After J&J to Acquire Co in $14.6 Bln Deal

THOMSON REUTERS
·
13 Jan

Johnson & Johnson to acquire Intra-Cellular for $132.00 per share in cash

TIPRANKS
·
13 Jan

Intra-Cellular Therapies Inc : Mizuho Raises Target Price to $140 From $100

THOMSON REUTERS
·
13 Jan

J&J to buy Intra-Cellular Therapies for $14.6 billion

Reuters
·
13 Jan

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

GlobeNewswire
·
13 Jan

Johnson & Johnson - Deal Valued at $14.6 Billion, $132 per Share

THOMSON REUTERS
·
13 Jan

Intra-Cellular Therapies Inc - Proposed Deal for $14.6 Bln

THOMSON REUTERS
·
13 Jan

Johnson & Johnson Strengthens Neuroscience Leadership With Acquisition of Intra-Cellular Therapies, Inc.

THOMSON REUTERS
·
13 Jan

Market Chatter: Johnson & Johnson in Talks to Acquire Intra-Cellular Therapies

MT Newswires Live
·
13 Jan

Johnson & Johnson in Talks to Acquire Intra-Cellular Therapies, Says Bloomberg

Dow Jones
·
13 Jan

Intra-Cellular Therapies Surges 32% As J&J Explores Bid for Biopharmaceutical Company

Tiger Newspress
·
13 Jan